English
Back
Open Account
HBM HOLDINGS
wrote a column · Sep 3, 2021 15:37

The trade fair is here! Hebo Pharmaceutical debuted in the health services sector

From September 2 to 7, 2021, the 2021 China International Trade in Services Fair (“Trade in Services”) with the theme of “Digitalization opens the future, service promotes development” was grandly held in Beijing. The “Trade in Services Fair” is one of the three major exhibitions China has opened to the outside world. It is the world's first national, international and comprehensive service trade platform. It is a display window, exchange platform and cooperation bridge for the service industry and trade in services. This year's trade fair has a total of 8 special exhibitions, covering finance, education, health services, etc. As a biopharmaceutical company focusing on the R&D, commercialization, and global operation of innovative drugs for cancer and immune diseases, Hebo Pharmaceutical made a wonderful appearance at the “Health and Health Services” conference. With the further deepening of medical reform, medical insurance catalogue adjustments, medical insurance price negotiations, and a new round of volume procurement have brought continuous challenges to drug prices. In particular, they have had a huge impact on the pricing of products with weak differences. At the same time, the exploration of health insurance payment method reforms has also pushed the industry to pay more attention to drug price-effectiveness. Hebo Pharmaceutical has always adhered to a differentiated product line layout guided by clinical value, carried out forward-looking clinical development, and accelerated its differentiation and world-leading product pipeline. The core products bartolizumab (HBM9161), tenacept (HBM9036), and Harbour Mice's self-developed product HBM4003 have all shown impressive clinical potential and are expected to benefit patients in China and around the world in the near future. New technology, new trends, and new opportunities are important for trade fairs...
From September 2 to 7, 2021, the 2021 China International Trade in Services Fair (“Trade in Services”) with the theme of “Digitalization opens the future, service promotes development” was grandly held in Beijing. The “Trade in Services Fair” is one of the three major exhibitions China has opened to the outside world. It is the world's first national, international and comprehensive service trade platform. It is a display window, exchange platform and cooperation bridge for the service industry and trade in services. This year's trade fair has a total of 8 special exhibitions, covering finance, education, health services, etc.and platinum medicineAs a biopharmaceutical company focusing on the R&D, commercialization and global operation of innovative drugs for cancer and immune diseases, a wonderful appearanceTrade fairs in services“Health and Hygiene Service” venue。
From September 2 to 7, 2021, the 2021 China International Trade in Services Fair (“Trade in Services”) with the theme of “Digitalization opens the future, service promotes development” was grandly held in Beijing. The “Trade in Services Fair” is one of the three major exhibitions China has opened to the outside world. It is the world's first national, international and comprehensive service trade platform. It is a display window, exchange platform and cooperation bridge for the service industry and trade in services. This year's trade fair has a total of 8 special exhibitions, covering finance, education, health services, etc. As a biopharmaceutical company focusing on the R&D, commercialization, and global operation of innovative drugs for cancer and immune diseases, Hebo Pharmaceutical made a wonderful appearance at the “Health and Health Services” conference. With the further deepening of medical reform, medical insurance catalogue adjustments, medical insurance price negotiations, and a new round of volume procurement have brought continuous challenges to drug prices. In particular, they have had a huge impact on the pricing of products with weak differences. At the same time, the exploration of health insurance payment method reforms has also pushed the industry to pay more attention to drug price-effectiveness. Hebo Pharmaceutical has always adhered to a differentiated product line layout guided by clinical value, carried out forward-looking clinical development, and accelerated its differentiation and world-leading product pipeline. The core products bartolizumab (HBM9161), tenacept (HBM9036), and Harbour Mice's self-developed product HBM4003 have all shown impressive clinical potential and are expected to benefit patients in China and around the world in the near future. New technology, new trends, and new opportunities are important for trade fairs...
With the further deepening of medical reform, medical insurance catalogue adjustments, medical insurance price negotiations, and a new round of volume procurement have brought continuous challenges to drug prices. In particular, they have had a huge impact on the pricing of products with weak differences. At the same time, the exploration of health insurance payment method reforms has also pushed the industry to pay more attention to drug price-effectiveness. Hebo Pharmaceutical has always adhered to a differentiated product line layout guided by clinical value, carried out forward-looking clinical development, and accelerated its differentiation and world-leading product pipeline. Core products bartolizumab (HBM9161), tenacip (HBM9036), and Harbour MiceThe self-developed product HBM4003 has shown impressive clinical potential and is expected to benefit patients in China and around the world in the near future.
From September 2 to 7, 2021, the 2021 China International Trade in Services Fair (“Trade in Services”) with the theme of “Digitalization opens the future, service promotes development” was grandly held in Beijing. The “Trade in Services Fair” is one of the three major exhibitions China has opened to the outside world. It is the world's first national, international and comprehensive service trade platform. It is a display window, exchange platform and cooperation bridge for the service industry and trade in services. This year's trade fair has a total of 8 special exhibitions, covering finance, education, health services, etc. As a biopharmaceutical company focusing on the R&D, commercialization, and global operation of innovative drugs for cancer and immune diseases, Hebo Pharmaceutical made a wonderful appearance at the “Health and Health Services” conference. With the further deepening of medical reform, medical insurance catalogue adjustments, medical insurance price negotiations, and a new round of volume procurement have brought continuous challenges to drug prices. In particular, they have had a huge impact on the pricing of products with weak differences. At the same time, the exploration of health insurance payment method reforms has also pushed the industry to pay more attention to drug price-effectiveness. Hebo Pharmaceutical has always adhered to a differentiated product line layout guided by clinical value, carried out forward-looking clinical development, and accelerated its differentiation and world-leading product pipeline. The core products bartolizumab (HBM9161), tenacept (HBM9036), and Harbour Mice's self-developed product HBM4003 have all shown impressive clinical potential and are expected to benefit patients in China and around the world in the near future. New technology, new trends, and new opportunities are important for trade fairs...
New technology, new trends, and new opportunities are one of the important highlights of the trade fair. Heplatinum Pharmaceuticals has always believed in the power of “new”. Only innovation can truly drive technological progress and help upgrade the industry.Since its inception, Hebai Pharmaceutical has carried out international innovative cooperation with the world's top academic institutions and biomedical companies. Through independent innovation and diversified cooperation, it has consolidated its own strength and the complementary advantages of its partners, continuously unleashed platform value, and comprehensively promoted the development process of next-generation innovative therapeutics.At the same time, the company also grants technical licenses to global biopharmaceutical companies and academic institutions to enhance the industry's ability to innovate and accelerate the introduction of more innovative therapies to patients.
01
From September 2 to 7, 2021, the 2021 China International Trade in Services Fair (“Trade in Services”) with the theme of “Digitalization opens the future, service promotes development” was grandly held in Beijing. The “Trade in Services Fair” is one of the three major exhibitions China has opened to the outside world. It is the world's first national, international and comprehensive service trade platform. It is a display window, exchange platform and cooperation bridge for the service industry and trade in services. This year's trade fair has a total of 8 special exhibitions, covering finance, education, health services, etc. As a biopharmaceutical company focusing on the R&D, commercialization, and global operation of innovative drugs for cancer and immune diseases, Hebo Pharmaceutical made a wonderful appearance at the “Health and Health Services” conference. With the further deepening of medical reform, medical insurance catalogue adjustments, medical insurance price negotiations, and a new round of volume procurement have brought continuous challenges to drug prices. In particular, they have had a huge impact on the pricing of products with weak differences. At the same time, the exploration of health insurance payment method reforms has also pushed the industry to pay more attention to drug price-effectiveness. Hebo Pharmaceutical has always adhered to a differentiated product line layout guided by clinical value, carried out forward-looking clinical development, and accelerated its differentiation and world-leading product pipeline. The core products bartolizumab (HBM9161), tenacept (HBM9036), and Harbour Mice's self-developed product HBM4003 have all shown impressive clinical potential and are expected to benefit patients in China and around the world in the near future. New technology, new trends, and new opportunities are important for trade fairs...
In May of this year, a strategic cooperation agreement was reached with Platinum Pharmaceuticals and Baitu Biotech to use Harbour MiceBased on the platform, it integrates Baitu Biotech's advantages in artificial intelligence technology, and is committed to scientific research, development and transformation of novel antibody products. (click for details)
02
From September 2 to 7, 2021, the 2021 China International Trade in Services Fair (“Trade in Services”) with the theme of “Digitalization opens the future, service promotes development” was grandly held in Beijing. The “Trade in Services Fair” is one of the three major exhibitions China has opened to the outside world. It is the world's first national, international and comprehensive service trade platform. It is a display window, exchange platform and cooperation bridge for the service industry and trade in services. This year's trade fair has a total of 8 special exhibitions, covering finance, education, health services, etc. As a biopharmaceutical company focusing on the R&D, commercialization, and global operation of innovative drugs for cancer and immune diseases, Hebo Pharmaceutical made a wonderful appearance at the “Health and Health Services” conference. With the further deepening of medical reform, medical insurance catalogue adjustments, medical insurance price negotiations, and a new round of volume procurement have brought continuous challenges to drug prices. In particular, they have had a huge impact on the pricing of products with weak differences. At the same time, the exploration of health insurance payment method reforms has also pushed the industry to pay more attention to drug price-effectiveness. Hebo Pharmaceutical has always adhered to a differentiated product line layout guided by clinical value, carried out forward-looking clinical development, and accelerated its differentiation and world-leading product pipeline. The core products bartolizumab (HBM9161), tenacept (HBM9036), and Harbour Mice's self-developed product HBM4003 have all shown impressive clinical potential and are expected to benefit patients in China and around the world in the near future. New technology, new trends, and new opportunities are important for trade fairs...
In June, a multi-year research cooperation agreement was reached with the Dana-Farber Cancer Institute (DFCI), an affiliated hospital of Harvard Medical School, to jointly promote research and development of innovative biological therapies for cancer treatment, including bispecific antibodies and CAR-T cell products. (click for details)
03
From September 2 to 7, 2021, the 2021 China International Trade in Services Fair (“Trade in Services”) with the theme of “Digitalization opens the future, service promotes development” was grandly held in Beijing. The “Trade in Services Fair” is one of the three major exhibitions China has opened to the outside world. It is the world's first national, international and comprehensive service trade platform. It is a display window, exchange platform and cooperation bridge for the service industry and trade in services. This year's trade fair has a total of 8 special exhibitions, covering finance, education, health services, etc. As a biopharmaceutical company focusing on the R&D, commercialization, and global operation of innovative drugs for cancer and immune diseases, Hebo Pharmaceutical made a wonderful appearance at the “Health and Health Services” conference. With the further deepening of medical reform, medical insurance catalogue adjustments, medical insurance price negotiations, and a new round of volume procurement have brought continuous challenges to drug prices. In particular, they have had a huge impact on the pricing of products with weak differences. At the same time, the exploration of health insurance payment method reforms has also pushed the industry to pay more attention to drug price-effectiveness. Hebo Pharmaceutical has always adhered to a differentiated product line layout guided by clinical value, carried out forward-looking clinical development, and accelerated its differentiation and world-leading product pipeline. The core products bartolizumab (HBM9161), tenacept (HBM9036), and Harbour Mice's self-developed product HBM4003 have all shown impressive clinical potential and are expected to benefit patients in China and around the world in the near future. New technology, new trends, and new opportunities are important for trade fairs...
In 2020, Hebo Pharmaceutical authorized the Greater China rights of three preclinical products (HBM7020, HBM1029, and HBM7015) developed on its own technology platform to the Chinese biopharmaceutical company Hualan Gene. The two companies used their respective advantages to jointly promote the development of these three projects. (click for details)
Today, trade fairs have become an important platform for China to promote a high level of opening-up to the outside world. During the “13th Five-Year Plan” period, China's total imports and exports of services reached 3.6 trillion US dollars, further consolidating its position as the second largest country in global trade in services. Hebo Pharmaceutical believes that with the rapid development of biotechnology in China, an ecological model where the healthcare industry is based in China and radiates the world has already begun, and the era of Chinese medicine traveling around the world is about to come.
About Hebo Pharmaceuticals
Hebo Pharmaceutical (stock code: 02142.HK) is a global biopharmaceutical company focusing on the development and commercialization of innovative drugs in the field of oncology and immune diseases. The company rapidly expands the innovative drug research and development pipeline through independent R&D, joint development and diversified cooperation models.
Harbour Mice, Hebo's own antibody technology platformIt can generate all-human monoclonal antibodies in the form of double, double light chain (H2L2), and heavy chain only (HCaB). Immune cell adaptor developed based on the HCaB antibody platform (HBICE)) It can achieve anti-tumor curative effects that cannot be achieved by traditional drug combination therapy. Harbour MiceTogether with the monoclonal B-cell screening platform, it formed Heplatinum's next-generation innovative therapeutic antibody development engine.
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
166K Views
Report
Comments
Write a Comment...
1